ArticleNature communications2026
Dual compartment lipid carriers hijack exocytosis to empower natural killer cells against solid tumours.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Solid tumours resist adoptive cell therapies through lactate driven immunosuppression, which depletes intracellular nicotinamide adenine dinucleotide, suppresses interferon gamma production in T cells, and reprogrammes macrophages. Here we show that a dual compartment lipid carrier system hijacks exocytosis for spatiotemporal metabolic reprogramming. Lipid nanoparticles deliver nicotinamide mononucleotide to restore intracellular nicotinamide adenine dinucleotide, while endoplasmic reticulum targeted carriers exploit the endoplasmic reticulum to Golgi pathway to achieve trafficking directed exocytic dichloroacetate export, enabling precise lactate depletion without systemic toxicity. This integrated approach rewires the metabolic landscape, extends natural killer cell persistence and reactivates cytolytic function. Endoplasmic reticulum engineered natural killer cells achieve potent tumour suppression through spatiotemporal metabolic reprogramming, a platform strategy that also extends to conventional T cell and macrophage therapies for enhanced therapeutic efficacy across adoptive cell systems. Our work establishes exocytosis co option as a strategy to empower cellular therapies and improve antitumour efficacy against lactate rich solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.